Transaction #4670 · Form 4 · 0001531178-25-000007
Vistagen Therapeutics, Inc. · Stock award · Stock Option (Right to Buy)
Vistagen Therapeutics, Inc. · Transacted October 27, 2025 · Filed November 4, 2025
What does this filing report?
An SEC Form 4 filing for Vistagen Therapeutics, Inc. records a stock award involving Stock Option (Right to Buy) on October 27, 2025. The reported quantity was 35,200. The filing date is November 4, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Vistagen Therapeutics, Inc.
- Company CIK
- 0001411685
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 35,200
- Reported price
- Not reported · See footnotes
- Reference value
- Not reported
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 35,200
- Ownership description
- Not reported
- SEC acceptance time
- Nov 4, 2025, 4:34 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Edick Paul R ↗
Director
CIK 0001531178
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 35,200
- Conversion / exercise price
- 3.9
- Exercise date
- Not reported
- Expiration date
- October 27, 2035
Filing footnotes & remarks
- F1
- Represents stock options granted in connection with the reporting person's appointment to the Issuer's Board of Directors. The stock options were granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended, and vest in three equal annual installments, beginning on the first anniversary of the date of the grant.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.